Hartman Institute for Therapeutic Organ Regeneration

Haematopoietic stem cell reprogramming and the hope for a universal blood product.

TitleHaematopoietic stem cell reprogramming and the hope for a universal blood product.
Publication TypeJournal Article
Year of Publication2019
AuthorsDurán JGabriel Ba, Lis R, Rafii S
JournalFEBS Lett
Volume593
Issue23
Pagination3253-3265
Date Published2019 Dec
ISSN1873-3468
KeywordsCell Differentiation, Cell Lineage, Cellular Reprogramming, Hematopoiesis, Hematopoietic Stem Cells, Humans, Induced Pluripotent Stem Cells, Transcription Factors
Abstract

<p>Haematopoietic stem cells (HSCs) are the only adult stem cells with a demonstrated clinical use, even though a tractable method to maintain and expand human HSCs in vitro has not yet been found. Owing to the introduction of transplantation strategies for the treatment of haematological malignancies and, more recently, the promise of gene therapy, the need to improve the generation, manipulation and scalability of autologous or allogeneic HSCs has risen steeply over the past decade. In that context, reprogramming strategies based on the expression of exogenous transcription factors have emerged as a means to produce functional HSCs in vitro. These approaches largely stem from the assumption that key master transcription factors direct the expression of downstream target genes thereby triggering haematopoiesis. Both somatic and pluripotent cells have been used to this end, yielding variable results in terms of haematopoietic phenotype and functionality. Here, we present an overview of the haematopoietic reprogramming methods reported to date, provide the appropriate historical context and offer some critical insight about where the field stands at present.</p>

DOI10.1002/1873-3468.13681
Alternate JournalFEBS Lett
PubMed ID31725897

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065